Key Takeaway: SAB BIO has activated over 60 clinical sites for its registrational SAFEGUARD study of SAB-142, targeting Stage 3 new onset type 1 diabetes. The company reports that enrollment is on schedule for completion by Q4 2026, with topline data anticipated in the latter half of 2027. Additionally, a grant has been awarded for the PRISE-hATG study of SAB-142.
Market Sentiment Analysis
POSITIVE FACTORS
Over 60 clinical sites activated for the SAFEGUARD study.
Enrollment for the study is on track for completion.
Topline data expected in the second half of 2027.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
25.7%
average across 4 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
SAB-142
Phase 3 · Type 1 Diabetes (T1D)
Full Press Release Details
Over 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE ‑ hATG study of SAB ‑ 142 in patients with Stage
Frequently Asked Questions
What is the SAFEGUARD study about?
The SAFEGUARD study is focused on SAB-142 for Stage 3 new onset type 1 diabetes.
How many clinical sites are activated for the study?
Over 60 clinical sites have been activated for the SAFEGUARD study.
When is the enrollment expected to complete?
Enrollment for the study is on track to complete in Q4 2026.
When will topline data be available?
Topline data from the study is expected in the second half of 2027.